In addition, clinical data showed that longer PFS and OS is clearly associated with lower PARP1 expression and higher p62 expression in patients with NSCLC after TKI therapy compared to their expression levels without TKI therapy. The gene discussed is PARP1; the disease is non-small cell lung carcinoma.